ZIM
ARIA

Zacks Investment Management’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Zacks Investment Management’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-265,676
Closed -$2.14M – 815
2014
Q1 		$2.14M Buy
+265,676
New +$2.07M 0.08% 173

Other funds holding ARIA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Zacks Investment Management's ARIA Position: Q2 2014 in Review

Zacks Investment Management sold out of Ariad Pharmaceuticals Inc (ARIA) in Q2 2014, closing a stake of 265,676 shares — an estimated $2.14M sold.

Zacks Investment Management first reported a position in ARIA in Q1 2014 and held it in 1 quarter. The position peaked at $2.14M in Q1 2014. 169 funds tracked by Wall St. Rank hold ARIA as of Q2 2014.

  • Zacks Investment Management reported no remaining Ariad Pharmaceuticals Inc position as of Q2 2014 after selling out during the quarter.
  • Zacks Investment Management sold 265,676 Ariad Pharmaceuticals Inc shares in Q2 2014, an estimated $2.14M.
  • Zacks Investment Management first reported a position in Ariad Pharmaceuticals Inc in Q1 2014 and held it in 1 quarter.
  • Zacks Investment Management's Ariad Pharmaceuticals Inc position peaked at $2.14M in Q1 2014.
  • 169 funds tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q2 2014.

Based on Zacks Investment Management's 13F filing for Q2 2014, filed 12 Aug 2014.